Compiled by Cari Kraft, Jacobs Management Group, Inc.
BY THE NUMBERS
Sales of in vitro diagnostics top
The leading device sector for the next
several years will continue to be in vitro
diagnostics, with projected sales of
$70.8B remain in 2022, more than 13%
of the industry’s total sales. Roche is
the leading company in this segment,
with its 2022 test sales forecast to
reach $12.8 billion.
Source: EvaluateMed Tech® World
Preview 2016, Outlook to 2022
Top 10 new molecular entities expected to grow
enormously in the next five years
Although the top molecular entities reached only $2 million
in sales in 2015, they are expected to grow to over $32 million
by 2020. These include Pfizer’s Ibrance, Gilead’s Genvoya,
Novartis’s Entresto, Vertex’s Orkambi and Amgen’s Repatha.
Source: EvaluatePharma World Preview 2016
Drug advertising budgets reach
Nielson estimated that $5.2 billion was
spent on prescription drug advertising
in 2015. Even as social media reaches
more people (see our last issue), the
largest chunk of that amount was
for television advertising. Two drugs
in particular were promoted on TV
the most. AbbVie spent $357 million
in 2015 in TV ads for Humira, and
Pfizer followed, with $328 million on
commercials for Lyrica.
Source: STAT, April 2016, based on
market reports from Kantar Media,
Nielsen, and iSpot.tv.
Number of doses of medicines worldwide
The global use of medicines is expected to reach
4. 5 trillion doses by 2020, costing $1.4 trillion.
The largest pharmaceutical-using countries will
be the pharmerging markets, accounting for
two-thirds of the global medicine usage, mostly
generic medicines. This dramatic uptick is largely
due to broad-based health system expansions.
Source: IMS Institute for Healthcare Informatics,
“Global Medicines Use in 2020: Outlook and
4. 5 T